Skip to content

Author

Leandra Serio

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Aspirin for primary prevention in patients with diabetes according to lipoprotein(a) levels: a real-world propensity-matched analysis

Aspirin may be considered for primary prevention in selected patients with diabetes mellitus (DM). Lipoprotein(a) [Lp(a)] is an independent cardiovascular risk factor linked to myocardial infarction and stroke and may promote thrombogenicity. Whether the association between aspirin use and cardiovascular outcomes...

M. Rossi, E. Tartaglia, A. Askarinejad et al. · 0 citations
Open access Oct 2026

Cardiovascular–kidney–metabolic risk stratification and cardiorenal outcomes with SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes: a global federated network study

A consistent cardiorenal benefit pattern was observed across low, moderate and high CKM strata, with SGLT2i reducing renal outcomes and GLP-1RA conferring greater cardiovascular protection.

C. Wang, A. Askarinejad, Y. Chen et al. · 0 citations
Open access Sep 2026

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network.

BACKGROUND AND AIM Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium-glucose cotransporter-2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with...

Leandra Serio, M. Rossi, A. Askarinejad et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.